HIV-1 envelope protein vaccine induces more robust antibody responses in infants than adults

Broadly neutralizing antibodies (bnAbs) develop more robustly in infants living with HIV-1 than adults, suggesting that vaccine-induced bnAbs may be more readily generated in infants. We evaluated a recombinant HIV-1 CH505TF gp120 monomer adjuvanted with GLA-SE in infants without HIV-1, born to mothers living with HIV-1, in a phase 1 randomized, placebo-controlled trial (HVTN135). Two weeks post-fifth dose, all vaccinated infants developed vaccine-specific CH505-positive B cells, IgG CH505TF gp120-specific binding antibodies (bAbs), and vaccine-matched Tier 1A neutralizing antibodies (nAbs); 86% had CD4 binding-site- (CD4bs) specific IgG + B cells and 43% had CD4bs-directed bAbs based on reduced binding to a CD4bs mutant (Δ371I). Compared to healthy adults from a harmonized phase 1 trial (HVTN115), infant IgG bAb titers and Tier 1A nAb ID50 titers were higher. Maternal antibody interference was not detected. Infant bAbs to routine immunizations were unaffected. These data support that infants can respond to a candidate adjuvanted HIV-1 vaccine with a greater magnitude of HIV-specific humoral responses than adults.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11626851/v1
Primary Topic
HIV Research and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

HIV-1 envelope protein vaccine induces more robust antibody responses in infants than adults

Sheetal S. Sawant, Kelly E. Seaton, David C. Montefiori, Genevieve G. Fouda et al.
Research Square
HIV Research and Treatment
preprint

HIV-1 envelope protein vaccine induces more robust antibody responses in infants than adults

Sheetal S. Sawant, Kelly E. Seaton, David C. Montefiori, Genevieve G. Fouda, Avy Violari, K. Rachael Parks, Kinga K. Smolen, Nonhlanhla N. Mkhize, Georgia D. Tomaras, Laura Polakowski, James J. Kobie, Guido Ferrari, Holly Janes, Troy M. Martin, Barton F. Haynes, Kennedy N. Otwombe, Kevin J. Wiehe, Lawrence Corey, Ofer Levy, Jack Heptinstall, Margaret Brewinski Isaacs, Prudence Kgagudi, Haajira Kaldine, Robert Parks, Wilton B. Williams, Magdalena E. Sobieszczyk, Penny L. Moore, Madison Berry, Glenda Gray, Lu Zhang, Yue Chen, Shiyu Chen, Amanda S Woodward Davis, William O. Hahn, Paul T Edelfsen, Mathew Clark
preprint en

Abstract

Broadly neutralizing antibodies (bnAbs) develop more robustly in infants living with HIV-1 than adults, suggesting that vaccine-induced bnAbs may be more readily generated in infants. We evaluated a recombinant HIV-1 CH505TF gp120 monomer adjuvanted with GLA-SE in infants without HIV-1, born to mothers living with HIV-1, in a phase 1 randomized, placebo-controlled trial (HVTN135). Two weeks post-fifth dose, all vaccinated infants developed vaccine-specific CH505-positive B cells, IgG CH505TF gp120-specific binding antibodies (bAbs), and vaccine-matched Tier 1A neutralizing antibodies (nAbs); 86% had CD4 binding-site- (CD4bs) specific IgG + B cells and 43% had CD4bs-directed bAbs based on reduced binding to a CD4bs mutant (Δ371I). Compared to healthy adults from a harmonized phase 1 trial (HVTN115), infant IgG bAb titers and Tier 1A nAb ID50 titers were higher. Maternal antibody interference was not detected. Infant bAbs to routine immunizations were unaffected. These data support that infants can respond to a candidate adjuvanted HIV-1 vaccine with a greater magnitude of HIV-specific humoral responses than adults.

Research Square
Boston Children's Hospital (US), Duke University (US), University of the Witwatersrand (ZA), Cornell University (US), University of Alabama at Birmingham (US), Fred Hutch Cancer Center (US), Duke Medical Center (US), National Institute of Allergy and Infectious Diseases (US), Weill Cornell Medicine (US)
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon